Open AccessMedicine

G. Kahaly, L. Bartalena, L. Hegedüs, L. Leenhardt, K. Poppe, S. Pearce

2018.7.25European Thyroid Journal

DOI: 10.1159/000490384

tlooto Summary

If a patient relapses after completing a course of ATD, definitive treatment is recommended; however, continued long-term low-dose MMI can be considered, and steroid prophylaxis is warranted in Graves’ patients with mild/active orbitopathy receiving RAI.

Abstract

Abstract is not available.

Citation format

KAHALY, G., et al. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. European Thyroid Journal, 2018, 7: 167–186.